Hubei Guangji Pharmaceutical Valuation

Is 000952 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 000952 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 000952's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 000952's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 000952?

Key metric: As 000952 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 000952. This is calculated by dividing 000952's market cap by their current revenue.
What is 000952's PS Ratio?
PS Ratio	3.4x
Sales	CN¥677.52m
Market Cap	CN¥2.30b

000952 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	5x
Enterprise Value/EBITDA	-73.7x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 000952's PS Ratio compare to its peers?

The above table shows the PS ratio for 000952 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3x
600774 Hanshang Group	1.8x	n/a	CN¥2.3b
300254 ShanXi C&Y Pharmaceutical GroupLTD	2.8x	n/a	CN¥2.3b
600080 Ginwa Enterprise (Group)	4.7x	n/a	CN¥2.7b
002873 Guiyang Xintian PharmaceuticalLtd	2.6x	17.4%	CN¥2.2b
000952 Hubei Guangji Pharmaceutical	3.4x	n/a	CN¥2.3b

Price-To-Sales vs Peers: 000952 is expensive based on its Price-To-Sales Ratio (3.4x) compared to the peer average (3x).

Price to Sales Ratio vs Industry

How does 000952's PS Ratio compare vs other companies in the CN Pharmaceuticals Industry?

6 Companies	Price / Sales	Estimated Growth	Market Cap
600664 Harbin Pharmaceutical Group	0.6x	n/a	US$1.30b
000411 Zhejiang Int'l GroupLtd	0.2x	n/a	US$790.12m
000153 Anhui Fengyuan Pharmaceutical	0.7x	n/a	US$413.04m
600781 FUREN Group PharmaceuticalLtd	0.3x	n/a	US$66.91m

6 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 000952 is good value based on its Price-To-Sales Ratio (3.4x) compared to the CN Pharmaceuticals industry average (3.6x).

Price to Sales Ratio vs Fair Ratio

What is 000952's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

000952 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	3.4x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 000952's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥49.3b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥31.05

3.7%

7.9%

Hunan Jiudian Pharmaceutical

CN¥11.8b

Researches, develops, produces, and sells pharmaceutical products in China and internationally.

300705

CN¥23.80

-1.8%

12.8%

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.20

-3.1%

-24.5%